ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

daridorexant

Also written as “Daridorexant”, “ACT-541468” and “Daridorexant 25 mg”.

Its studies are mostly in Sleep Initiation and Maintenance Disorders · Sleep Apnea, Obstructive · Renal Insufficiency · Pulmonary Disease, Chronic Obstructive, led by 3 companies.

Drug pageDaridorexant: every studyAll 46 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Oct 25, 202234 company-led studies, 1 open or runningNext primary completion: Nov 22, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Idorsia Pharmaceuticals311 open or runningphase 4since Oct 25, 2022Aug 14, 2015Nov 22, 2027phase 3 · NCT07843329
Simcere Pharmaceutical Groupits history only20 open or runningphase 3since Aug 20, 2023Aug 20, 2023none ahead
Nxera Pharma Koreaits history only10 open or runningphase 3since Jun 11, 2025Jun 11, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Idorsia Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 14 studies since Aug 14, 2015.

  1. Oct 18, 2018Phase 1 study in Hepatic ImpairmentNCT03713242 · 32 enrolled · Switzerland
  2. Dec 4, 2018Phase 1 study in Sleep Apnea, ObstructiveNCT03765294 · 28 enrolled · Germany
  3. Jan 8, 2019Phase 1 study in HealthyNCT03799978 · 20 enrolled · Czechia
  4. Mar 21, 20192 phase 1 studies in HealthyNCT03907215, NCT03892902
  5. Jul 16, 2019Phase 1 study in Renal InsufficiencyNCT04024332 · 16 enrolled · Germany
  6. Jan 30, 2020Phase 1 study in HealthyNCT04250506 · 36 enrolled · Czechia
  7. May 12, 2020Phase 1 study in HealthyNCT04390334 · 24 enrolled · Germany
  8. Jun 14, 2022Phase 2 study in Sleep Initiation and Maintenance DisordersNCT05423717 · 166 enrolled · United States, Bulgaria, Germany and more
  9. Jul 11, 20223 phase 1 studiesNCT05458193, NCT05480488, NCT05480475
  10. Oct 25, 2022Phase 4 study in Sleep Initiation and Maintenance DisordersNCT05597020 · 60 enrolled · United States, Germany, Spain
  11. Nov 8, 2022Phase 1 study in HealthyNCT05632393 · 10 enrolled · United States
  12. Jan 5, 2023Phase 1 study in HealthyNCT05702177 · 36 enrolled · Netherlands
  13. May 17, 2023Phase 1 study in HealthyNCT05877222 · 38 enrolled · United States
  14. Sep 21, 2026Phase 3 study in Insomia DisorderNCT07843329 · 344 planned · United States

Ahead

  1. Nov 22, 2027Primary completion: phase 3 study in Insomia DisorderNCT07843329

TargetBeta

“Orexin receptor antagonist; Orexin receptor 1 antagonist; Orexin receptor 2 antagonist”ChEMBL 37, by rule

Studies

All 31 Idorsia Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07843329Insomia Disorder · United States3RecruitingNov 22, 2027344
NCT05877222Healthy · United States1CompletedAug 4, 202338
NCT05702177Healthy · Netherlands1CompletedApr 25, 202336
NCT05632393Healthy · United States1CompletedApr 30, 202310
NCT05597020Sleep Initiation and Maintenance Disorders · United States, Germany, Spain4CompletedApr 12, 202460
NCT05480488Healthy · Germany1CompletedSep 23, 202218
NCT05480475Healthy · Czechia1CompletedSep 17, 202224
NCT05458193Obstructive Sleep Apnea of Adult · Germany1CompletedFeb 28, 202320
NCT05423717Sleep Initiation and Maintenance Disorders · United States, Bulgaria, Germany and more2CompletedJan 12, 2026166
NCT04390334Healthy · Germany1CompletedJun 26, 202024
NCT04250506Healthy · Czechia1CompletedJul 22, 202036
NCT04024332Renal Insufficiency · Germany1CompletedAug 14, 202016
NCT03907215Healthy · Germany1CompletedJun 26, 201924
NCT03892902Healthy · Netherlands1CompletedOct 10, 201956
NCT03799978Healthy · Czechia1CompletedMar 18, 201920
NCT03765294Sleep Apnea, Obstructive · Germany1CompletedNov 5, 201928
NCT03713242Hepatic Impairment · Switzerland1CompletedFeb 27, 202032
NCT03679884Sleep Initiation and Maintenance Disorders · United States, Belgium, Bulgaria and more3CompletedFeb 22, 2021804
NCT03657355Healthy Recreational Drug Users · United States, Canada1CompletedAug 8, 201963
NCT03646864Pulmonary Disease, Chronic Obstructive · Germany1CompletedSep 19, 201928
NCT03609775Healthy · Netherlands1CompletedOct 9, 201822
NCT03545191Sleep Initiation and Maintenance Disorders · United States, Australia, Canada and more3CompletedJan 25, 2020930
NCT03575104Sleep Initiation and Maintenance Disorders · United States, Belgium, Bulgaria and more3CompletedApr 9, 2020924
NCT03339752Healthy Subjects · Czechia1CompletedDec 2, 201720
NCT03101189Healthy Subjects · Netherlands1CompletedApr 24, 201740
NCT03017495Healthy Subjects · Germany1CompletedFeb 1, 201720
NCT02919319Healthy Subjects · Netherlands1CompletedMay 1, 201540
NCT02841709Sleep Initiation and Maintenance Disorders · United States, Germany2CompletedMay 31, 201758
NCT02839200Sleep Initiation and Maintenance Disorders · United States, Germany, Hungary and more2CompletedApr 12, 2017360
NCT02571855Sleep Initiation and Maintenance Disorders · Netherlands1CompletedFeb 1, 201685
NCT02526888Healthy Subjects · Germany1CompletedNov 1, 201514

How it is read

Names in the registry

  • “Daridorexant”, 12 entries
  • “ACT-541468”, 12 entries
  • “Daridorexant 25 mg”, 5 entries
  • “Daridorexant 50 mg”, 4 entries
  • “Daridorexant 10 mg”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.